Maria Nikita, Artemis Doulgeraki, Margarita Baka, Charalampos Tsentidis, George Polyzois, Helen Athanasopoulou, Dimitrios Doganis, Theodora Anastasiou, Varvara Douna, Lydia Kossiva
{"title":"儿童恶性血液病诊断时骨矿物质状况。","authors":"Maria Nikita, Artemis Doulgeraki, Margarita Baka, Charalampos Tsentidis, George Polyzois, Helen Athanasopoulou, Dimitrios Doganis, Theodora Anastasiou, Varvara Douna, Lydia Kossiva","doi":"10.1080/08880018.2025.2487435","DOIUrl":null,"url":null,"abstract":"<p><p>Reduced bone mineral density (BMD) has been reported during and after treatment of children with hematologic malignancies. However, little is known about the skeletal status of these patients at diagnosis. The aim of this study was to evaluate the skeletal profile of newly diagnosed pediatric patients with Acute lymphoblastic leukemia (ALL), Hodgkin Lymphoma (HL), and Non-Hodgkin Lymphoma (NHL). A case-control study included 50 children with ALL, 11 with HL, and 10 with NHL and compared them to 108 sex- and age-matched controls. Patients underwent bone metabolism evaluation and dual-energy X-ray absorptiometry (DXA) scan at the time of diagnosis. Seventy-one children were evaluated (43 boys) with a median age of 8.25 years (2.16-17.33 years). Twenty-one with ALL had bone pain (16 with a limp pain) at diagnosis. More than half (59.1%) of the patients were vitamin D sufficient (25-ΟΗ-<i>D</i> > 20 ng/ml). Patients had lower values of serum procollagen type I C-terminal propeptide (PICP), osteocalcin (OC), and tartrate-resistant acid phosphatase (bTRAP5b) (<i>p</i> < 0.001) than controls. A DXA scan was performed in 45 patients. Patients with ALL and Lymphoma had lower values of Lumbar Spine (L1-L4, LS) BMD Z-score (<i>p</i> < 0.001, <i>p</i> < 0.01, respectively) while those with ALL had lower values of Total Body Less Head (ΤBLH) BMD Z-score (<i>p</i> = 0.003) than controls. Skeletal health is adversely affected in pediatric patients with ALL and Lymphoma at diagnosis. These observations support bone health surveillance in cancer patients and timely intervention starting at the time of diagnosis.</p>","PeriodicalId":19746,"journal":{"name":"Pediatric Hematology and Oncology","volume":" ","pages":"205-216"},"PeriodicalIF":1.2000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Bone mineral status at diagnosis οf children with hematologic malignancy.\",\"authors\":\"Maria Nikita, Artemis Doulgeraki, Margarita Baka, Charalampos Tsentidis, George Polyzois, Helen Athanasopoulou, Dimitrios Doganis, Theodora Anastasiou, Varvara Douna, Lydia Kossiva\",\"doi\":\"10.1080/08880018.2025.2487435\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Reduced bone mineral density (BMD) has been reported during and after treatment of children with hematologic malignancies. However, little is known about the skeletal status of these patients at diagnosis. The aim of this study was to evaluate the skeletal profile of newly diagnosed pediatric patients with Acute lymphoblastic leukemia (ALL), Hodgkin Lymphoma (HL), and Non-Hodgkin Lymphoma (NHL). A case-control study included 50 children with ALL, 11 with HL, and 10 with NHL and compared them to 108 sex- and age-matched controls. Patients underwent bone metabolism evaluation and dual-energy X-ray absorptiometry (DXA) scan at the time of diagnosis. Seventy-one children were evaluated (43 boys) with a median age of 8.25 years (2.16-17.33 years). Twenty-one with ALL had bone pain (16 with a limp pain) at diagnosis. More than half (59.1%) of the patients were vitamin D sufficient (25-ΟΗ-<i>D</i> > 20 ng/ml). Patients had lower values of serum procollagen type I C-terminal propeptide (PICP), osteocalcin (OC), and tartrate-resistant acid phosphatase (bTRAP5b) (<i>p</i> < 0.001) than controls. A DXA scan was performed in 45 patients. Patients with ALL and Lymphoma had lower values of Lumbar Spine (L1-L4, LS) BMD Z-score (<i>p</i> < 0.001, <i>p</i> < 0.01, respectively) while those with ALL had lower values of Total Body Less Head (ΤBLH) BMD Z-score (<i>p</i> = 0.003) than controls. Skeletal health is adversely affected in pediatric patients with ALL and Lymphoma at diagnosis. These observations support bone health surveillance in cancer patients and timely intervention starting at the time of diagnosis.</p>\",\"PeriodicalId\":19746,\"journal\":{\"name\":\"Pediatric Hematology and Oncology\",\"volume\":\" \",\"pages\":\"205-216\"},\"PeriodicalIF\":1.2000,\"publicationDate\":\"2025-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pediatric Hematology and Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/08880018.2025.2487435\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/4/17 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Hematology and Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/08880018.2025.2487435","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/17 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
骨密度降低(BMD)已报道期间和治疗后的儿童血液恶性肿瘤。然而,对这些患者在诊断时的骨骼状况知之甚少。本研究的目的是评估新诊断的急性淋巴细胞白血病(ALL)、霍奇金淋巴瘤(HL)和非霍奇金淋巴瘤(NHL)患儿的骨骼特征。一项病例对照研究包括50名ALL患儿,11名HL患儿和10名NHL患儿,并将他们与108名性别和年龄匹配的对照组进行比较。患者在诊断时接受骨代谢评估和双能x线吸收仪(DXA)扫描。71名儿童(43名男孩)被评估,中位年龄为8.25岁(2.16-17.33岁)。21例ALL患者在诊断时有骨痛(16例伴有跛行疼痛)。超过一半(59.1%)的患者维生素D充足(25-ΟΗ-D bbb20 ng/ml)。患者血清I型前胶原c末端前肽(PICP)、骨钙素(OC)和抗酒石酸酸性磷酸酶(bTRAP5b)值低于对照组(p p p p = 0.003)。诊断为ALL和淋巴瘤的儿童患者骨骼健康受到不利影响。这些观察结果支持对癌症患者进行骨骼健康监测,并从诊断时开始及时干预。
Bone mineral status at diagnosis οf children with hematologic malignancy.
Reduced bone mineral density (BMD) has been reported during and after treatment of children with hematologic malignancies. However, little is known about the skeletal status of these patients at diagnosis. The aim of this study was to evaluate the skeletal profile of newly diagnosed pediatric patients with Acute lymphoblastic leukemia (ALL), Hodgkin Lymphoma (HL), and Non-Hodgkin Lymphoma (NHL). A case-control study included 50 children with ALL, 11 with HL, and 10 with NHL and compared them to 108 sex- and age-matched controls. Patients underwent bone metabolism evaluation and dual-energy X-ray absorptiometry (DXA) scan at the time of diagnosis. Seventy-one children were evaluated (43 boys) with a median age of 8.25 years (2.16-17.33 years). Twenty-one with ALL had bone pain (16 with a limp pain) at diagnosis. More than half (59.1%) of the patients were vitamin D sufficient (25-ΟΗ-D > 20 ng/ml). Patients had lower values of serum procollagen type I C-terminal propeptide (PICP), osteocalcin (OC), and tartrate-resistant acid phosphatase (bTRAP5b) (p < 0.001) than controls. A DXA scan was performed in 45 patients. Patients with ALL and Lymphoma had lower values of Lumbar Spine (L1-L4, LS) BMD Z-score (p < 0.001, p < 0.01, respectively) while those with ALL had lower values of Total Body Less Head (ΤBLH) BMD Z-score (p = 0.003) than controls. Skeletal health is adversely affected in pediatric patients with ALL and Lymphoma at diagnosis. These observations support bone health surveillance in cancer patients and timely intervention starting at the time of diagnosis.
期刊介绍:
PHO: Pediatric Hematology and Oncology covers all aspects of research and patient management within the area of blood disorders and malignant diseases of childhood. Our goal is to make PHO: Pediatric Hematology and Oncology the premier journal for the international community of clinicians and scientists who together aim to define optimal therapeutic strategies for children and young adults with cancer and blood disorders. The journal supports articles that address research in diverse clinical settings, exceptional case studies/series that add novel insights into pathogenesis and/or clinical care, and reviews highlighting discoveries and challenges emerging from consortia and conferences. Clinical studies as well as basic and translational research reports regarding cancer pathogenesis, genetics, molecular diagnostics, pharmacology, stem cells, molecular targeting, cellular and immune therapies and transplantation are of interest. Papers with a focus on supportive care, late effects and on related ethical, legal, psychological, social, cultural, or historical aspects of these fields are also appreciated. Reviews on important developments in the field are welcome. Articles from scientists and clinicians across the international community of Pediatric Hematology and Oncology are considered for publication. The journal is not dependent on or connected with any organization or society. All submissions undergo rigorous peer review prior to publication. Our Editorial Board includes experts in Pediatric Hematology and Oncology representing a wide range of academic and geographic diversity.